Prostate and bladder cancer screening

Journal of the American College of Surgeons

Volumn 186, Issue 1, 1998, Pages 63-74

  Goldstein, Martin M ^a   Messing, Edward M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEAR PROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER SCREENING; CHROMOSOME ABERRATION; CYSTECTOMY; CYTOLOGY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FINGER; FLOW CYTOMETRY; HEMATURIA; HUMAN; MALE; MORTALITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RECTUM; TRANSITIONAL CELL CARCINOMA; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0031889910     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(97)00150-6     Document Type: Article

References (58)

1. Wingo PA, Tong T, and Bolden S. Cancer statistics. Cancer 1995;45:8-30.
2. Potosky AL, Miller BA, Albertson PC, and Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-552.
3. Miller BA, Ries LAG, Hankey BF, et al, eds. Cancer Statistics Review: 1973-1989. NIH publication no. 92-2789. Bethesda, MD: National Cancer Institute; 1992.
4. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examinations and serum prostate specific antigen in the early detection of prostate cancer: results of a multicentered clinical trial of 6,630 men. J Urol 1994;151:1283-1290.
5. Richie JP, Catalona WJ, Ahmann FR, et al. Effect of patient age on early detection of prostate cancer with serum prostate specific antigen and digital rectal examination. Urology 1993;42: 365-374.
6. Boring CC, Squires TS, Tong T, and Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
7. Catalona WJ, Smith DS, Ratliff TL, and Basler JW Detection of organ confined prostate cancer is increased through prostate specific antigen based screening. JAMA 1993;270:948-954.
8. Gerber GS, Thompson IM, Thisted R, and Chodak GW Disease specific survival following routine prostate cancer screening by digital rectal examination. JAMA 1993;269:61-64.
9. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
10. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147: 841-845.
11. Catalona WJ. Screening for prostate cancer: enthusiasm. Urology 1993;42:113-115.
12. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate specific antigen testing. JAMA 1985;274:1445-1449.
13. Smith DS, Catalona WJ, and Hersaschman JD. Longitudinal screening for prostate cancer with prostate specific antigen. JAMA 1996;276:1309-1315.
14. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostatic cancer. J Urol 1992;147:815-816.
15. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen (PSA) concentration versus prostate specific antigen density (PSAD) in the early detection of prostate cancer: receiver operation characteristics (ROC) curves. J Urol 1994;152: 2031-2036.
16. Oesterling JE, Jacobsen SJ, Schute CG, et al. Serum specific antigen in the community based population of healthy men: establishment of age specific reference ranges. JAMA 1992;270: 860-864.
17. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen (PSA) cutoffs for early detection of prostate cancer: receiver operating characteristics (ROC) curves. J Urol 1994;152:2037-2042.
18. Carter HB, Pearson JD, Mettler EJ, et al. Longitudinal evaluation of PSA levels in men with and without prostate disease. JAMA 1992;267:2215-2220.
19. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-1220.
20. Catalona WJ, Smith DS, and Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/ml and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-1455.
21. Miller BA, et al, eds. Cancer Statistics Review: 1973-1989. NIH publication no. 92-2789. National Cancer Institute; 1992.
22. Steele GD Jr, Osteen RT, Winchester DP, et al. Clinical highlights from the national cancer database: 1994. Ca Cancer J Clin 1994;44:71-80.
23. Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate 1990;17:337-347.
24. Johansson JE, Holmberg L, Johansson S, et al. Fifteen year survival in prostate cancer. A prospective, population based study in Sweden. JAMA 1997;277:467-471.
25. Albertsen PC, Fryback DG, Storer BE, et al. Long term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-631.
26. Parker SL, Tong T, Bolden S, and Wingo PA. Cancer statistics 1997. Ca Cancer J Clin 1997;47:5-27.
27. Kaye KW, and Lange PH. Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol 1992;128:31-33.
28. Prout GR Jr, Barton PA, Griffin PP, et al. Treated history of non-invasive grade I transitional cell carcinoma. J Urol 1992;148: 1413-1419.
29. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-1086.
30. Marshall VF. Current clinical problems regarding bladder tumors. Cancer 1956;3:543-550.
31. Messing EM, and Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med 1990;32:835-845.
32. Messing EM, Young TB, Hunt BB, et al. The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J Urol 1987;137:919-922.
33. Greene LF, O'Shaughnessy EJ Jr, and Hendricks ED. Study of 500 patients with asymptomatic microhematuria. JAMA 1956;161: 610-613.
34. Carson CC III, Segura JW, and Greene LF. Clinical importance of microhematuria. JAMA 1979;241:149-150.
35. Golin AL, and Howard RS. Asymptomatic microscopic hematuria. J Urol 1980;124:389-391.
36. Thompson IM. The evaluation of microscopic hematuria: a population based study. J Urol 1987;138:1189-1190.
37. Messing EM, Young TB, Hunt VB, et al. Urinary tract cancers found by home screening with hematuria dipsticks in healthy men over 50 years of age. Cancer 1989;64:2361-2367.
38. Messing EM, Young TB, Hunt VB, et al. Home screening for hematuria: results of a multiclinic study. J Urol 1992;148: 289-292.
39. Messing EM, Young TB, Hunt VB, et al. Hematuria home screening: repeat testing results. J Urol 1995;154:57-61.
40. Britton JP, Dowell AC, and Whelan P. Dipstick haematuria and bladder cancer in men over 60: results of a community study. BMJ 1989;299:1010-1012.
41. Britton JP, Dowell AC, Whelan P, et al. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992;148:788-790.
42. Messing EM, and Catalona WJ. Urethral tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughn ED, and Wein AJ, eds. Campbell's Urology, 7th ed. Philadelphia: WB Saunders 1998:2354-2357.
43. Lawrence WF, Messing EM, and Bram LL. The cost effectiveness of screening men for bladder cancer using chemical reagent strips to detect microscopic hematuria. Abstract presented at the 1995 Annual Meeting of the American Urological Association, April 27, 1995, Las Vegas, NV.
44. Messing EM, and Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med 1990;32:838-845.
45. Wheeless LL, Reeder JE, Han R, et al. Bladder irrigation specimens assay by fluorescence in situ hybridization to interphase nuclei. Cytometry 1994;17:319-326.
46. Mao L, Schoenberg MP, Scicchitano M, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271:659-662.
47. Brentnall TA. Microsatellite instability: shifting concepts in tumorigenesis. Am J Pathol 1995;147:561-563.
48. Steiner G, Scoenberg MP, Linn JF, et al. Detection of bladder cancer recurrence by macrosatellite analysis of urine. Nature Med 1997;3:621-624.
49. Golijanin D, Sherman Y, Shapiro A, and Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine [Review]. Urology 1995;46:173-177.
50. Bonner RB, Hemstreet GP III, Fradet Y, et al. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer 1993;72:2461-2469.
51. Grossman HB, Washington RW Jr, Care TE, and Liebert HB. Alterations in antigen expression in superficial bladder cancer [Review]. J Cell Biochem Suppl 1992;161:63-68.
52. Fradet Y, Tardif M, Bourget L, et al. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Cancer Res 1990;50: 432-437.
53. Huland E, Huland H, Meier TH, et al. Comparison of 15 monoclonal antibodies against tumor associated antigens of transitional cell carcinoma of the human bladder. J Urol 1991;146:1631-1636.
54. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990;50:2530-2537.
55. Mellon K, Wright C, Kelly P, et al. Long term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995;153:1919-1925.
56. Guirguis R, Schiffmann E, Liu B, et al. Detection of autocrine motility factor in urine as a marker of bladder cancer. J Natl Cancer Inst 1988;80:1203-1211.
57. D'Hallewin M, and Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 1996;155: 475-476.
58. Soloway MS, Briggman JB, Carpinigo GA, et al. Use of the new tumor marker, urinary NMP 22, in detection of occult or rapidly recurring transitional cell carcinoma of urinary tract following surgical treatment. J Urol 1996;156:363-367.